Sector practice head — Pharma & Biotech (Continental Europe) · CTO

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CTO leadership mandate anchored in Continental Europe. The remit explicitly spans Africa, Canada, China.

This is a sector or practice-head mandate combining deep domain credibility with commercial ownership of a vertical P&L or global practice line.

The mandate fits a leader comfortable owning the narrative externally while upgrading how decisions are made internally.

Context you will inherit

• Market & sector: Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
• Geographic spine: Primary hub Continental Europe with explicit corridor responsibility across Africa, Canada, China.
• Organisation stage: ESG and conduct expectations from owners and regulators are now hard constraints on how growth is pursued.
• Stakeholders: Owners may include PE operating partners, a promoter family office, or public-market investors — each with different tempo and KPIs.
• Secondary lens: R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership

The mandate (12–24 month arc)

1. Product-aligned tech: Tighten partnership with product and GTM so roadmaps reflect customer and revenue reality.
2. Cost of technology: Drive FinOps discipline — visibility, accountability, and trade-offs on build vs. buy.
3. Innovation portfolio: Balance horizon-one delivery with selective bets on differentiating capabilities.
4. Technical standards: Publish and enforce patterns that reduce one-off solutions across teams.
5. Regulatory tech: Where sector demands, ensure systems and controls satisfy audit and supervisor expectations.
6. Leadership communication: Make technology risk and opportunity legible to non-technical boards and investors.

Responsibilities (representative)

• Drive platform consolidation where fragmentation hurts speed or cost.
• Establish technical programme management for large migrations or rewrites.
• Improve engineering metrics — lead time, change failure rate, incident trends.
• Represent technology risk and opportunity clearly to board and investors.
• Ensure regulatory expectations on systems are met in financial services, health, etc.

Leadership profile

• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Scale experience: Systems and organisations that grew materially under your technology leadership.
• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Communication: Executive presence in English; additional languages valued where market-relevant.
• Geographic muscle: Comfort operating from Continental Europe with regular engagement across Africa, Canada.

Team & culture

You inherit a mixed-tenure team — pockets of excellence beside roles that need upgrade. The mandate is to raise the bar without demoralising the organisation: clear standards, fair process, and visible wins that prove the new pace is achievable.

Success measures (examples)

• Growth quality: Mix of recurring revenue, new logos, and cross-sell — not volume for its own sake.
• Productivity: Unit cost, automation savings, or throughput improvements with audited baselines.
• Customer: NPS / CSAT where tracked; contract renewals; reference-ability in strategic accounts.
• Franchise: Clean compliance record; reputation stability in industry and government forums.

First 90 days (orientation arc)

• Days 1–30: Listening tour — customers, regulators (as appropriate), top team 1:1s, and unfiltered view of numbers; pause major reorganisation.
• Days 30–60: Publish a short memo on priorities, non-goals, and decision rights; align executive committee on three enterprise bets.
• Days 60–90: Lock operating cadence; fill or upgrade one to two critical seats; deliver one visible win (customer, cost, or culture).
• Commission a pragmatic view of data, cyber, and automation posture; sponsor one bounded pilot with ROI hypothesis.
• Establish escalation discipline with matrix partners — fewer meetings, clearer decision logs.

Stakeholder map (illustrative)

• Internal: CEO or regional president, CFO, risk / legal, CHRO, CIO or CDO, business GMs, internal audit.
• External: Strategic accounts, channel partners, industry associations, regulators (where material).
• Owners: PE operating partners, promoter office, or public investors — pace and clarity matter as much as vision.

Travel & mobility

Travel weighted to priority markets and quarterly global or regional forums; flexibility for crisis windows.

Compensation

Market-aligned CTO remuneration in Pharmaceuticals & Biotechnology with performance linkage; sign-on and relocation considered for exceptional fits.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and Continental Europe. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CTO · Continental Europe · Gladwin International Leadership Advisors